- Home
- OI vs CNTA Comparison
OI vs CNTA Comparison
Compare OI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | CNTA |
|---|---|---|
| Founded | 1903 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 3.5B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OI | CNTA |
|---|---|---|
| Price | $10.48 | $28.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $17.57 | ★ $40.89 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 04-28-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,426,000,000.00 | N/A |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.23 | $9.60 |
| 52 Week High | $16.91 | $30.58 |
Technical Indicators
Market Signals| Indicator | OI | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 24.09 | 65.08 |
| Support Level | N/A | $24.62 |
| Resistance Level | $13.46 | $30.29 |
| Average True Range (ATR) | 0.53 | 1.27 |
| MACD | -0.15 | 0.19 |
| Stochastic Oscillator | 1.03 | 93.32 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.